Pharmacologic treatment of cognition in Alzheimer's dementia

Martin R. Farlow, Rebecca M. Evans

Research output: Contribution to journalArticle

67 Scopus citations

Abstract

Much of the treatment research and development for Alzheimer's disease (AD) in recent years has been based on the cholinergic hypothesis. Cholinesterase inhibition has been shown to improve the symptoms of mild to moderate AD. Two cholinesterase inhibitors (CIs) are now available and two more may be available shortly. Free radical inhibitors, estrogen, and anti- inflammatory drugs may also delay the onset and slow progression of AD. Combination therapies employing CIs and these other drugs may prove successful in the future.

Original languageEnglish (US)
Pages (from-to)S36-S44
JournalNeurology
Volume51
Issue number1 SUPPL.
StatePublished - Aug 5 1998

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Pharmacologic treatment of cognition in Alzheimer's dementia'. Together they form a unique fingerprint.

  • Cite this